Ionis Pharmaceuticals(IONS) - 2023 Q4 - Annual Results

Exhibit 99.1 Ionis reports fourth quarter and full year 2023 financial results WAINUATM approved with launch underway; on track for EU and Canada approval decisions this year (1) Reconciliation of GAAP to non-GAAP basis contained later in this release. 1 Financial Highlights Recent Marketed Medicines Highlights Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthrough Therapy designation by the FDA for FCS Ionis provides f ...